Behavioral motor recovery in the 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-lesioned squirrel monkey (Saimiri sciureus): Changes in striatal dopamine and expression of tyrosine hydroxylase and dopamine transporter proteins

Journal of Neuroscience Research

Volumn 83, Issue 2, 2006, Pages 332-347

  Petzinger, Giselle M ^a,b   Fisher, Beth ^b   Hogg, Elizabeth ^a   Abernathy, Avery ^a   Arevalo, Pablo ^a   Nixon, Kerry ^a   Jakowec, Michael W ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Basal ganglia; Neuroplasticity; Nonhuman primate; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3,4 DIHYDROXYPHENYLACETIC ACID; DOPAMINE; DOPAMINE TRANSPORTER; HOMOVANILLIC ACID; PHOSPHOPROTEIN DARPP 32; TYROSINE 3 MONOOXYGENASE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL GANGLION; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOHISTOCHEMISTRY; MALE; MOTOR PERFORMANCE; NERVE CELL PLASTICITY; NEUROLOGIC DISEASE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RATING SCALE; SQUIRREL MONKEY; WESTERN BLOTTING;

ANIMALS; BEHAVIOR, ANIMAL; BLOTTING, WESTERN; CELL COUNT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE AND CAMP-REGULATED PHOSPHOPROTEIN 32; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; IMMUNOHISTOCHEMISTRY; MALE; MOTOR ACTIVITY; MPTP POISONING; RECOVERY OF FUNCTION; SAIMIRI; TIME FACTORS; TYROSINE 3-MONOOXYGENASE;

EID: 31844445273     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.20730     Document Type: Article

References (64)

1. Abercrombie ED, Bonatz AE, Zigmond MJ. 1990. Effects of L-DOPA on extracellular dopamine in striatum of normal and 6-hydroxydopamione-treated rats. Brain Res 525:36-44.
2. Altar CA, Marien MR. 1989. Preservation of dopamine release in the denervated striatum. Neurosci Lett 96:329-334.
3. Anderson KD, Reiner A. 1991. Immunohistochemical localization of DARPP-32 in striatal projection neurons and striatal interneurons: implications for the localization of D1-like dopamine receptors on different types of striatal neurons. Brain Res 568:235-243.
4. Bezard E, Dovero S, Imbert C, Boraud T, Gross CE. 2000. Spontaneous long-term compensatory dopaminergic sprouting in MPTP-treated mice. Synapse 38:363-368.
5. Boyce S, Rupniak MJ, Steventon MJ, Iverson SD. 1990a. Nigrostriatal damage is required for induction of dyskinesias by L-DOPA in squirrel monkeys. Clin Neuropharmacol 13:448-458.
6. Boyce S, Rupniak NMJ, Steventon MJ, Iverson SD. 1990b. Characterization of dyskinesias induced by L-dopa in MPTP-treated squirrel monkeys. Psychopharmacology 102:21-27.
7. Burns RS. Chiueh CC, Markey SP, Eben MH, Jacobowitz DM, Kopin IJ. 1983. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine. Proc Natl Acad Sci USA 80:4546-4550.
8. Castaneda E, Whishaw IQ, Robinson TE. 1990. Changes in striatal dopamine neurotransmission assessed with microdialysis following recovery trom a bilateral 6-OHDA lesion: variation as a function of lesion size. J Neurosci 10:1847-1854.
9. Chiba K, Peterson LA, Castagnoli KP, Trevor AJ, Castagnoli N. 1985. Studies on the molecular mechanism of bioactivation of the selective nigrostriatal toxin 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine. Drug Metab Dispos 13:342-347.
10. Creese I, Burt DR, Snyder SH. 1977. Dopamine receptor binding enhancement accompanies lesion-induced behavioral sensitivity. Science 197:596-598.
11. Dauer W, Przedborski S. 2003. Parkinson's disease. Mechanisms and models. Neuron 39:889-909.
12. Elsworth JD, Deutch AY, Redmond DE, Sladek JR, Roth RH. 1990. MPTP-induced parkinsonism: relative changes in dopamine concentration in subregions of substantia nigra, ventral tegmental area and retrorubal field of symptomatic and asymptomatic vervet monkeys. Brain Res 513:320-324.
13. Elsworth JD, Taylor JR, Sladek JR, Collier TJ, Redmond DE, Roth RH. 2000. Striatal dopaminergic correlates of stable parkinsonism and degree of recovery in old-world primates one year after MPTP treatment. Neuroscience 95:399-408.
14. Emmers R, Akert K. 1963. A stereotaxic atlas of the brain of the squirrel monkey (Saimiri sciureus). Madison: The University of Wisconsin Press.
15. Finkelstem DI, Stanic D, Parish CL, Tomas D, Dickson K, Horne MK. 2000. Axonal sprouting following lesions of the rat substantia nigra. Neuroscience 97:99-112.
16. Fisher B, Petzinger GM, Nixon K, Hogg E, Bremmer S, Meshul C, Jakowec MW. 2004. Exercised induced behavioral recovery and neuroplasticity in the 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine-lesioned mouse basal ganglia. J Neurosci Res 77:378-390.
17. Frohna PA, Neal-Beliveau BS, Joyce JN. 1997. Delayed plasticity of the mesolimbic dopamine system following neonatal 6-OHDA lesions. Synapse 25:293-305.
18. Gainetdinov RR, Sotnikova TD, Caron MG. 2002. Monoamine transporter pharmacology and mutant mice. Trends Pharmacol Sci 23:367-373.
19. Gerfen CR. 2000. Molecular effects of dopamine on striatal-projection pathways. Trends Neurosci 23(Suppl):S64-S70.
20. Gnanalingham KK, Milkowski NA, Smith LA, Hunter AJ, Jenner P, Marsden CD. 1995. Short- and long-term changes in striatal and extrastriatal dopamine uptake sites in the MPTP-treated common marmoset. Eur J Pharmacol 277:235-241.
21. Greengard P, Allen PB, Nairn AC. 1999. Beyond the dopamine receptor: the DARPP-32/protein phosphatase-1 cascade. Neuron 23:435-447.
22. Gundersen HJ, Jensen EB. 1987. The efficiency of systematic sampling in stereology and its prediction. J Microsc 147:229-263.
23. Hollerman JR, Grace AA. 1990. The effects of dopamine-depleting brain lesions on the electrophysiological activity of rat substantia nigra dopamine neurons. Brain Res 533:203-212.
24. Irwin I, Finnegan KT, DeLanney LE, Di Monte D, Langston JW. 1992. The relationship between aging, monoamine oxidase, striatal dopamine and the effects of MPTP in C57BL/6 mice: a critical reassessment. Brain Res 572:224-231.
25. Jakowec MW, Nixon K, Hogg L, McNeill T, Petzinger GM. 2004. Tyrosine hydroxylase and dopamine transporter expression following 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine-induced neurodegeneration in the mouse nigrostriatal pathway. J Neurosci Res 76:539-550.
26. Jakowec MW, Petzinger GM. 2004. 1-Methyl-4-phenyl-1, 2,3,6- tetrahydropyridine-lesioned model of Parkinson's disease, with emphasis on mice and nonhuman primates. Comp Med 54:497-513.
27. Kilpatrick IC, Jones MW, Phillipson OT. 1986. A semiautomated analysis method for catecholamines, indoleamines, and some prominent metabolites in microdissected regions of the nervous system: an isocratic HPLC technique employing coulometric detection and minimal sample preparation. J Neurochem 46:1865-1876.
28. Kurlan R, Kim MH, Gash DM. 1991. The time course and magnitude of spontaneous recovery of parkinsomsm produced by intracarotid administration of 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine to monkeys. Ann Neurol 29:677-679.
29. Laemmli UK. 1970. Cleavage of structural proteins during the assembly of the head of the bacteriophage T4. Nature 227:680-685.
30. Langston JW, Ballard P, Tetrud JW, Irwin I. 1983. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219:979-980.
31. Langston JW, Forno S, Rebert CS, Irwin I. 1984. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1, 2,5,6,-tetrahydropyridine (MPTP) in the squirrel monkey. Brain Res 292:390-394.
32. Marshall JF, Gotthelf T. 1979. Sensory inattention in rats with 6-hydroxydopamine-induced degeneration of ascending dopaminergic neurons: apomorphine-induced reversal of deficits. Exp Neurol 65:398-411.
33. Marshall JF, Teitelbaum P. 1974. Further analysis of sensory inattention following lateral hypothalamic damage in rats. J Comp Physiol Psychol 86:375-395.
34. Mitsumoto Y, Watanabe A, Mori A, Koga N. 1998. Spontaneous regeneration of nigrostriatal dopaminergic neurons in MPTP-treated C57BL/6 mice. Biochem Biophys Res Comm 248:660-663.
35. Nishi A, Snyder GL, Greengard P. 1997. Bidirectional regulation of DARPP-32 phosphorylation by dopamine. J Neurosci 17:8147-8155.
36. Nishi A, Watanabe Y, Higashi H, Tanaka M, Nairn AC, Greengard P. 2005. Glutamate regulation of DARPP-32 phosphorylation in neostriatal neurons involves activation of multiple signaling cascades. Proc Natl Acad Sci USA 102:1199-1204.
37. Onn S, Berger TW, Stricker EM, Zigmond MJ. 1986. Effects of intraventricular 6-hydroxydopamine on the dopaminergic innervation of striatum: histochemical and neurochemical analysis. Brain Res 376: 8-19.
38. Ouimet CC, Miller PE, Hemmings HC, Walaas SI, Greengard P. 1984. DARPP-32, a dopamine- and adenosine 3′:5′-monophosphate-regulated phosphoprotein enriched in dopamine-innervated brain regions. III. Immunocytochemical localization. J Neurosci 4:111-124.
39. Petzinger GM, Langston JW. 1998. The MPTP-lesioned non-human primate: a model for Parkinson's disease. In: Marwah J, Teitelbaum H, editors. Advances in neurodegenerative disease. Volume I. Parkinson's disease. Scottsdale, AZ: Prominent Press, p 113-148.
40. Petzinger GM, Quik M, Ivashina E, Jakowec MW, Jakubiak M, Di Monte D, Langston JW. 2001. Reliability and validity of a new global dyskinesia rating scale in MPTP-lesioned non-human primate. Mov Disord 16:202-207.
41. Raisman-Vozari R, Girault JA, Moussaoui S, Feuerstein C, Jenner P, Marsden CD, Agid Y. 1990. Lack of change in striatal DARPP-32 levels following nigrostriatal dopaminergic lesions in animals and in parkinsonian syndromes in man. Brain Res 507:45-50.
42. Robinson TE, Wishaw IQ. 1988. Normalization of extracellular dopamine in striatum following recovery from a partial unilateral 6-OHDA lesion of the substantia nigra: a microdialysis study in freely moving rats. Brain Res 450:209-224.
43. Rose S, Nomoto M, Jenner P, Marsden CD. 1989a. Transient depletion of nucleus accumbens dopamine content may contribute to initial akinesia induced by MPTP in common marmosets. Biochem Pharmacol 38:3677-3681.
44. Rose S, Nomoto M, Kelly E, Kilpatrick G, Jenner P, Marsden CD. 1989b. Increased caudate dopamine turnover may contribute to the recovery of motor function in marmosets treated with the dopaminergic neurotoxin MPTP. Neurosci Lett 101:305-310.
45. Rothblat DS, Schneider JS. 1994. Spontaneous functional recovery from parkinsonism is not due to reinnervation of the dorsal striatum by residual dopaminergic neurons. Brain Res Bull 34:309-312.
46. Rothblat DS, Schneider JS. 1995. Repeated exposure to MPTP does not produce a permanent movement disorder in cats recovered from MPTP-induced parkinsonism. Neurodegeneration 4:87-92.
47. Rothblat DS, Schneider JS. 1999. Regional differences in striatal dopamine uptake and release associated with recovery from MPTP-induced parkinsonism: an in vivo electrochemical study. J Neurochem 72:724-733.
48. Rothblat DS, Schroeder JA, Schneider JS. 2001. Tyrosine hydroxylase and dopamine transporter expression in residual dopaminergic neurons: Potential contributors to spontaneous recovery from experimental parkinsonism. J Neurosci Res 65:254-266.
49. Schneider JS. 1989. Levodopa-induced dyskinesias in parkinsonian monkeys: relationship to extent of nigrostriatal damage. Pharmacol Biochem Behav 34:193-196.
50. Schneider JS, Rothblat DS. 1991. Neurochemical evaluation of the striatum in symptomatic and recovered MPTP-treated cats. Neuroscience 44:421-429.
51. Schneider JS, Rothblat DS, DiStefano L. 1994. Volume transmission of dopamine over large distances may contribute to recovery from experimental parkinsonism. Brain Res 643:86-91.
52. Schneider JS, Schroeder JA, Rothblat DS. 1998. Differential recovery of sensorimotor function in GM1 ganglioside-treated vs. spontaneously recovered MPTP-treated cats: partial striatal dopaminergic reinnervation vs. neurochemical compensation. Brain Res 813:82-87.
53. Sedelis M, Hofele K, Auburger GW, Morgan S, Huston JP, Schwarting RK. 2000. MPTP susceptibility in the mouse: behavioral, neurochemical, and histological analysis of gender and strain differences. Behav Genet 30:171-182.
54. Sedelis M, Schwarting RK, Huston JP. 2001. Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. Behav Brain Res 125:109-125.
55. Tillerson JL, Cohen AD, Philhower J, Miller GW, Zigmond MJ, Schauert T. 2001. Forced limb-use effects on the behavioral and neurochemical effects of 6-hydroxydopamine. J Neurosci 21:4427-4435.
56. Towbin H, Staehelin T, Gordon J. 1979. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets. Procedures and some applications. Proc Natl Acad Sci USA 76:4350-4354.
57. Ueki A, Chong PN, Albanese A, Rose S, Chivers JK, Jenner P, Marsden CD. 1989. Further treatment with MPTP does not produce parkinsonism in marmosets showing behavioral recovery from motor deficits induced by an earlier exposure to the toxin. Neuropharmacology 28:1089-1097.
58. Ungerstedt U. 1971. Postsynaptic supersensitivity after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol Scand (Suppl) 367:69-93.
59. Vallone D, Picetti R, Borrelli E. 2000. Structure and function of dopamine receptors. Neurosci Biobehav Rev 24:125-132.
60. Wang WW, Cao R, Rao ZR, Chen LW. 2004. Differential expression of NMDA and AMPA receptor subunits in DARPP-32-containing neurons of the cerebral cortex, hippocampus and neostriatum of rats. Brain Res 998:174-183.
61. Zhang WQ, Tilson HA, Nanry KP, Hudson PM, Hong JS, Stachowiak MK. 1988. Increased dopamine release from striata of rats after unilateral nigrostriatal bundle damage. Brain Res 461:335-342.
62. Zigmond MJ, Abercrombie ED, Berger TW, Grace AA, Sticker EM. 1990. Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci 13:290-295.
63. Zigmond MJ, Acheson AL, Stachowiak MK, Strickerman EM. 1984. Neurochemical compensation after nigrostriatal bundle injury in an animal models of preclinical parkinsonism. Arch Neurol 41:856-861.
64. Zigmond MJ, Stricker EM. 1973. Recovery of feeding and drinking by rats after intraventricular 6-hydroxydopamine or lateral hypothalamic lesions. Science 182:717-720.